Ashley Dalton
MP for West Lancashire · Labour · United Kingdom
“My right hon. Friend is being very generous; I thank him for giving way. It was my sombre privilege to work with him on this matter when I was a Minister in the Department of Health.”
“I recently visited the Liberty Centre in my constituency, a fantastic charitable organisation that supports individuals and families who have been affected by domestic abuse and violence. It told me that it could fill its refuge places three times over, but it does not have the resources.”
“It can be diagnosed after a primary diagnosis—primary breast cancer is potentially curable—or the first time that a person is diagnosed with breast cancer. That is called a de novo diagnosis. That is what secondary breast cancer is and, as we have heard, I have it, along with many, many other people.”
“There is also a myth that the treatment for your primary cancer was somehow wrong or had failed if you get metastatic breast cancer. Again, that is absolute nonsense. Breast cancer can still spread, even after successful treatment for a primary cancer, and even with the best treatments in the world.”
“As ever, it is an honour to serve under your chairmanship, Mr Betts. I first acknowledge the campaigners from Make 2nds Count, METUP UK and Breast Cancer Now and the fellow MBC patients who are joining us in the Public Gallery.”
“I do not say that to terrify people, but to say that it is absolutely imperative that they are aware of the signs and symptoms of secondary breast cancer in case they ever have them, no matter how long it has been since their primary diagnosis—or indeed, if they have ever had one.”
The complete record
Every one of 602 lines we hold for Ashley Dalton, in date order, each linked to its source. Free to read, in full, without an account. Page 9 of 13.
“We are awaiting an update on progress on making dose counter inhalers dominant in the supply chain from the pharmaceutical industry. I will be more than happy to update the House when we have it. I thank my hon. Friend the Member for Bournemouth West (Jessica Toale), who focused on air quality, which is a priority for the Government and part of our prevention strategy, and the technology to help to manage asthma. There are a range of technologies available to help people to manage their asthma, and NHS England and NICE are exploring the potential for the platforms for digital self-management of asthma to be evaluated, but that depends on the technology readiness level.”
“However, approximately 89% of prescription items are dispensed free of charge in the community in England and a wide range of exemptions are already in place. Eligibility depends on factors such as the patient’s age and whether they are in qualifying full-time education, are pregnant, have recently given birth or are in receipt of certain benefits. People on low incomes can apply for help with their health costs through the NHS low income scheme. Children are of course entitled to free prescriptions. NHS England’s children and young people’s transformation team have been working closely with the MHRA on dose counters being added to inhalers. The “British National Formulary for Children” has been updated with guidance and supportive resources for patients and clinicians, which have been widely shared.”
“It is a pleasure to serve under your chairship, Dr Huq. I thank the hon. Member for Strangford (Jim Shannon) for bringing this timely debate forward as we mark last week’s World Asthma Day. It shows real leadership from the chair of the APPG for respiratory health. In that spirit, I would be delighted to take him up on his offer of a meeting. We will arrange that as soon as we possibly can—I am keen to do it. I thank hon. Members for their contributions. I am more than happy to meet the hon. Member for Birmingham Perry Barr (Ayoub Khan) to discuss the issues that he raised, including prescription charges. There are currently no plans to review the list of medical conditions that entitle someone to apply for a medical exemption certificate.”
“Yes, I confirm that I will write to the shadow Minister on FeNO at a later date. NHS England is also piloting a digital annual asthma check. I am sorry, Dr Huq, this is highly irregular, but I am feeling extremely unwell; I need to go and make myself okay. [ Interruption. ] Thank you for your forbearance, Dr Huq. Crohn’s is not something that we have debated in this Chamber; if we did, no doubt I would be the responding Minister, and I can assure you that I would be able to speak from personal expertise.”
“I am sure that he would agree that World Asthma Day is not just for raising awareness; it should also be a celebration of the great things that people with asthma have accomplished. I did not know this until I saw the research for this debate, but past asthmatics have included Dickens, Disraeli and Beethoven. If those examples seem archaic, I can also point to Harry Styles, Jessica Alba and David Beckham, as well as to many prominent Olympic medallists. People with asthma achieve great things. It is our job in this place to help them to reach their full potential, with a particular focus on addressing how respiratory conditions affect people in deprived communities.”
“On the changes to NHS England, we are abolishing NHS England in itself, but none of its functions is disappearing. We are working really closely across the Department and NHS England, as well as with our ICB colleagues, to ensure that all services are transferred in an appropriate way. The purpose of the changes is to make things as efficient and targeted as possible and to ensure that they get to the people who need them the most. Ensuring that community diagnostic centres are supported is really important to the Government, as it is very much part of one of our three shifts: from hospital to community. Those shifts—the other two are from sickness to prevention and from analogue to digital—are at the very heart of the 10-year plan. I thank the hon. Member for Strangford for bringing forward the debate.”
“I have talked about the stakeholder engagement that was really important in that, and I can guarantee that, with the 10-year strategic plan for the NHS, we will look right across the board at how we can make sure that all conditions get due consideration. During our short interruption, I was able to get a little more information for the shadow Minister on FeNO. Wessex Academic Health Science Network has created a FeNO rapid uptake product delivery toolkit, which is providing downloadable tools and resources to support NHS organisations with the adoption and implementation of FeNO testing to improve outcomes. Anyone can access that toolkit, which contains case studies of best practice identified through the programme. I hope that is helpful.”
“Yes, I will come to many of those issues. As I was saying, NHS England is piloting a digital annual asthma check, which, if successful, will mean that fewer people miss that valuable check and will keep the monitoring of their asthma up to date. The Lib Dem spokesperson, the hon. Member for Chichester (Jess Brown-Fuller), asked about the public health grant. The grant has been increased and local directors of public health are best placed to identify where to target resources in their communities. As I have said, the 10-year health plan will be published next month. It will cover all conditions and will consider lung health.”
“Friend the Member for Mitcham and Morden noted, NHS England has suspended its medicines repurposing programme, but not because it is unimportant; it has shown that opportunities to use existing medicines in new ways can be delivered without the support of a formal repurposing programme, including, for example, through local off-label prescribing. This creates opportunities for NIHR and other funders to support proposals for clinical trials that use repurposed drugs for rare cancers. We will help researchers work with industry and clinicians to strengthen the evidence base for new drugs, and for new uses of drugs, so that we can find out how patients can best be helped.”
“We will bust bureaucracy, fast-track clinical trials and give patients improved access to cutting-edge treatments and technologies, including for brain tumours. “Be Part of Research” is our landmark service, allowing people from all walks of life across the UK to find and participate in research relevant to them, which could transform lives. I urge everybody watching at home to sign up to “Be Part of Research” and to get involved. We have spoken about medicines repurposing, whereby medicines approved for a particular condition are used in new ways to treat different conditions. Repurposing drugs may have particular value for rare cancers, such as brain cancers, for which drug development has been limited. As my hon.”
“That is driving a “right research, right setting” initiative, and we are moving from reactive to proactive portfolio management, including by supporting the workforce and continuing to embed a research and innovation culture across the health and social care system. The Government also support the private Member’s Bill on rare cancers, brought forward by my hon. Friend the Member for Edinburgh South West (Dr Arthur). The Bill will make it easier for clinical trials on rare cancers to take place in England by ensuring that the patient population can be easily contacted. This Government are committed to backing innovative clinical research ecosystems in the UK, so that British patients can be among the first to benefit.”
“Clinical trials are a crucial part of cancer research. They are the key to advanced medical progress, improved patient outcomes and more hope for the future. Britain is already one of the best destinations in the world for clinical trials, but we want to go further. On 7 April, the Prime Minister announced action to accelerate the set-up and delivery of clinical trials; the time taken to set up studies will be cut to 150 days by March next year, down from 250 days, according to the latest data, which was collected in 2022. The Department of Health and Social Care is committed to being a world-leading destination for clinical trials. Work is ongoing to streamline and reform the set-up and delivery of clinical trials through digitalisation, and by reducing unnecessary bureaucracy.”
“Friend the Member for Mitcham and Morden raised the issue of partnerships with industry to develop treatments, and I can confirm that we are committed to working with the pharmaceutical industry and others with the common aim of creating a faster, more efficient, more accessible and innovative clinical treatment delivery system. We expect these efforts to attract more commercial investment in clinical research, and to yield a broad and diverse portfolio of clinical trials in the UK, so that we can provide innovative treatment options for patients, including those with glioblastoma. The new brain tumour research consortium, to which I have referred, will bring together people to work on that, and will work to detect, manage and treat rarer and less survivable cancers in children and adults.”
“My Department is now focusing on how we grow the scientific community working on brain cancer to get more research funded. We are committed to increasing spending on brain cancer research, and the £40 million target is not a funding ceiling—it will not end there. However, it is important that only high-quality applications be funded, so that public funds are invested well and produce impactful and usable research evidence. We will continue to work hand in glove with partners who fund research on new scientific discoveries, such as Cancer Research UK, the Medical Research Council and brain tumour charities. We stand ready to translate these much-needed discoveries as quickly as possible into new treatments for patients via the NIHR. My hon.”
“Thirdly, the Department is working actively as a member of the Tessa Jowell Brain Cancer Mission to fully support the vision of bringing the best care to all brain tumour patients in the UK. Together, we will work with the brain tumour community to accelerate research and bring new insights to the field. This summer, the mission will launch the Tessa Jowell allied health professional research fellowship to train early-career health professionals in conducting vital research on how we improve patients’ quality of life. The commitment to spend at least £40 million on brain cancer remains in place. The limiting factor has not been restrictions on funding, or funds being spent elsewhere, and every research proposal assessed as being fundable has been funded.”
“First, in September, the NIHR announced a new package of funding opportunities for brain cancer research for both adults and children. Secondly, in December, the NIHR established a new national brain tumour research consortium. The consortium brings together research from a range of disciplines and institutions to drive faster scientific advancements in how we prevent, detect, manage and treat brain cancer. This complements the NIHR’s dedicated funding call on research into wraparound care, rehabilitation and quality of life for patients with brain tumours. It has received a high volume of applications, and those applications are under consideration by an independent expert peer review panel.”
“In addition, over five years, between 2020 and 2024, the Medical Research Council committed more than £18.5 million to brain tumour research. Our investments are having an impact. NIHR-funded research has shown that a new targeted drug combination treatment can give better outcomes for one of the most common types of paediatric brain cancer, but of course there is still so much more to do. Too little is known about how to prevent, diagnose and manage brain tumours, and they remain one of the hardest cancers to treat and a challenging area for research. That is why we are committed to furthering our investment in brain cancer research and have already taken some steps to stimulate scientific progress. I would like to offer the House just three examples from the past year.”
“Innovative research is vital in our fight against this devastating disease if we are to offer people the most cutting-edge treatments and the highest-quality care. The Department of Health and Social Care, through the National Institute for Health and Care Research, invests over £1.6 billion per year in research. In the past financial year alone, it invested over £130 million specifically in cancer research. That has enabled 261 brain tumour studies to happen in the NHS, involving 11,400 people in potentially life-changing research over the past six years. Since 2018, the NIHR has directly invested almost £12 million in brain tumour research projects; it has also spent around £37.5 million on wider infrastructure investments in facilities, services and the research workforce, making research possible.”
“Member for North Shropshire (Helen Morgan), the Liberal Democrat spokesperson, talked about low-grade tumours. I commend her constituents, whom she spoke about, for their work. I thank the shadow Minister, the hon. Member for Hinckley and Bosworth (Dr Evans), for sharing the story of Isla’s stones. What a powerful metaphor and a powerful remembrance. He also spoke about the acquired brain injury strategy. My remarks will focus on brain tumours, but I can confirm that the ABI strategy remains in play and in development. I will update the House on that as soon as possible. First, I pay tribute to some fantastic charities for their advocacy—the Brain Tumour Charity, Brain Tumour Research, Cancer Research UK and Tom’s Trust, to name just a few.”
“I hope my responses will answer their queries, but if not, I will endeavour to write to all Members following this debate about any gaps that are left. The hon. Member for Edinburgh West (Christine Jardine) spoke about disparity of drug access. My right hon. Friend the Member for Hayes and Harlington (John McDonnell) asked for zest, and spoke about the requirement for it. He expressed the frustrations of the APPG and others at the speed at which we are able to make progress. The hon. Member for Strangford (Jim Shannon) spoke about the importance of research, and my hon. Friend the Member for Bolton West (Phil Brickell) spoke about clinical trials. The hon. Member for Leicester South (Shockat Adam) brought his expertise on optometry to bear, and spoke about how useful an eye test can be. The hon.”
“I thank my hon. Friend the Member for Mitcham and Morden (Dame Siobhain McDonagh) and the hon. Member for Witney (Charlie Maynard) for securing this vitally important debate. They have both been powerful voices in this place for more research, greater care and better treatments for patients with brain tumours. My hon. Friend spoke so powerfully, as always, and in the name of her sister Margaret. I thank the hon. Member for Witney for sharing his sister’s story. I commend her for her fundraising activity and wish her the very best. The hon. Member asked three very clear questions, which I hope my response will cover. I also thank other Members who made powerful contributions in what has been a very constructive debate.”
“Through our targeted package of support, that is what we will do. We completely understand the strength of feeling on this issue, not least because three Ministers in the Department of Health and Social Care are cancer survivors. We know how terrifying it is to receive a diagnosis. We have sat in waiting rooms, hoping for good news and fearing the worst—and we have heard the worst. We have had those difficult conversations with our loved ones and seen the devastating impact on their lives. That is why we are committed to making a real difference for patients with brain cancer. We will leave no stone unturned until they get the first-class care that they deserve. I look forward to further discussing how we can achieve this when I meet members of the all-party parliamentary group on brain tumours next week.”
“The Liberal Democrat spokesperson also talked about low-grade cancers. There is a difference between staging and grading, and it is important that we are clear about that. Low-grade brain tumours are considered non-cancerous, and they grow more slowly and are less likely to spread, but although low-grade brain tumours are generally non-cancerous, they can have similar serious symptoms, and require surgery or radiotherapy to treat them. The Government are investing in new life-saving and life-improving research to support people diagnosed with those cancers. In closing, for those affected by this devastating disease, every discovery, every treatment and every moment matters. We recognise that more needs to be done to stimulate high-quality, high-impact research into brain tumours.”
“768, c. 2WC.] (Correction) But we must go further, and we will. Our reforms to cancer care will see more than 100,000 people diagnosed faster, and thousands more starting treatment within two months across the NHS. There is no single solution to this complex challenge. That is why my right hon. Friend, the Secretary of State, has been clear that there will be a national cancer plan published later this year. This plan will ensure that rarer cancers, including brain cancers, will not be left behind. It is my absolute privilege, as a person with cancer, to be driving that cancer plan. I am delighted that we have so far received more than 11,000 representations as part of the call for evidence. I can assure my hon. Friend the Member for Mitcham and Morden that her contributions and all others will be taken seriously.”
“The NHS is focused on improving diagnostic waiting times, and on providing MRI, CT and other tests to reduce cancer waits, because, as Lord Darzi’s investigation has shown, we face significant challenges if we are to bring this country’s cancer survival rates back up to the standard of the best in the world. We know that the best way to improve survival for those with brain tumours, and with all cancers, is to diagnose patients early and treat them quickly. In our first six months, 80,000 more patients received a diagnosis or an all-clear within 28 days than did in the previous year, thanks to investment in cutting NHS waiting lists. In March, more than 80% of patients in England referred for cancer had it ruled out or diagnosed within 28 days—it is the first time that target has been met in years. [ Official Report , 2 June 2025; Vol.”
“NHS England has found that creating that environment does not necessarily provide new and better ways of repurposing drugs, and that can be done far more efficiently and far less bureaucratically by using local off-label prescribing. We are looking at how we can incentivise researchers and clinical trials to explore repurposing drugs. We are determined to make the NIHR and other funders grasp opportunities to support those proposals. We will help researchers work with industry and clinicians to strengthen the evidence base for new drugs. The NHS is working hard to diagnose and treat cancers on time. There is more to do on early diagnosis and faster treatment, in order to improve patient experience and survival.”
“We are already using technology to improve preventive healthcare and to transform the NHS. We have invested £11 million in artificial intelligence to trial breast cancer screening mammogram interpretation. We are piloting the NHS health check online to tackle cardiovascular disease, and our NHS Better Health digital products, including the award-winning Couch to 5K app, were used by millions of people last year to tackle preventable conditions. More will be included in the 10-year health plan.”
“I commend the work that my hon. Friend refers to. The new HealthTech innovation hub—a flagship project of the West Yorkshire investment zone—brings together West Yorkshire combined authority, organisations like the HealthTech Leeds partnership, academics, clinicians, policymakers and more than 250 health tech firms headquartered in the region. They are already driving forward health innovation together. As we have said before, we must learn about the best of the NHS and take it to the rest of the NHS. The 10-year plan will shift us to a model in which the NHS focuses on prevention, with more services delivered in local communities through new technologies.”
“And he has just sold me on what a wonderful charity it is. I would be more than happy to make sure that the relevant Minister meets the hon. Member to discuss the matter.”
“We are committed to fixing the front door of the NHS, including by delivering the primary care infrastructure required to enable a neighbourhood health service. We have already taken steps to improve primary care infrastructure, including by providing £100 million of capital funding to upgrade GP buildings. We will set out how we will move to a neighbourhood health service in our upcoming 10-year plan, following the spending review.”
“I do agree, and I would be delighted to work with my hon. Friend on the Government’s commitment to delivering a neighbourhood health service that reinforces integrated working for the NHS, local government, social care and wider partners as the norm.”
“I thank the right hon. Member for recognising the significant investment announced today in GP services and buildings, and I would be delighted to ensure that the relevant Minister meets her.”
“I add my heartfelt condolences to Arlo’s family. In September, we launched a new series of funding opportunities designed to improve brain cancer research for both adults and children. We are committed to furthering our investment and support for high-quality brain tumour research, ensuring that funding is used in the most meaningful and impactful way. Hon. Members will note that there is a debate on Thursday on brain tumours, and I will be attending the all-party parliamentary group on brain tumours next week.”
“I agree with my hon. Friend. We are making great strides in developing our cancer plans. We will be launching a national cancer plan later this year, and the targeted lung cancer screening programme has been particularly effective. The SNP has had a record settlement for Holyrood, and we expect the Scottish Government to deliver. If they cannot, I am sure that Anas Sarwar and Jackie Baillie would be willing to take over.”
“I do not have an update on the social care talks, but I will ensure that the Minister for Care hears that the matter has been raised in the debate. I once again extend my thanks to my hon. Friend the Member for Dunfermline and Dollar for securing the debate and to all Members who have spoken. I look forward to working with them all to ensure that people living with Parkinson’s have the dignity they deserve. I began by talking about Parkinson’s Awareness Month. One thing that struck me from hearing so many people share their stories, and from the stories shared in the debate, was the number who felt uncomfortable sharing their status, sometimes even with their close friends and family. This past month has been about smashing the stigma, and I know that this debate will play its part in that too.”
“It will reflect the fact that our NHS is caring for patients with increasingly complex needs. However, we are already making progress on the workforce to support those with Parkinson’s, including by having over 900 full-time equivalent consultants—over 30 more than in 2023. There are 27 specialised neurology centres across England. As of January, over 7,700 full-time equivalent speech and language therapists are employed in NHS trusts—an increase of over 300 compared to last year. There are over 17,900 full-time equivalent occupational therapists—an increase of over 600. As of January, there are almost 25,300 full-time equivalent physiotherapists—over 900 more than last year. We have also had a record increase in the carer’s allowance.”
“Neurology services have been facing real challenges, including in the workforce, delays to treatment and care, and a lack of information and support for patients. Through the forthcoming NHS 10-year health plan, we will improve care for people with long-term conditions like Parkinson’s. In response to the hon. Member for Meriden and Solihull East, I can confirm that the plan will drive our ambition towards greater use of technology and data in the NHS. A core part of the 10-year health plan will be our workforce and how we ensure that we train and provide the staff the NHS needs to make it more accessible, proactive and tailored for patients. The refreshed NHS workforce plan will set out the numbers of doctors, nurses and other professionals that will be needed in five, 10 and 15 years’ time.”
“It is revolutionary because it provides a continuous 24-hour infusion of medication via a small pump, providing more consistent symptom control. The NHS rolled it out in February last year. It has been shown to improve motor function and has proved its worth by significantly improving the quality of life of those with advanced Parkinson’s. I briefly remind colleagues that the NHS in England is legally required to make funding available for treatments recommended by technology appraisal guidance published by the National Institute for Health and Care Excellence. We all want to see people with Parkinson’s live as well as possible for as long as possible. That is why it is not good enough that we still see inequalities in access to Parkinson’s services.”
“The centre, supported by five of the National Institute for Health and Care Research’s biomedical research centres, has discovered that eye scans can detect Parkinson’s disease up to seven years before symptoms appear, enabling people to receive treatment and make any appropriate lifestyle changes earlier. I reassure the House that changes to the structure of NHS England and the Department will seek to eliminate duplication and improve efficiencies to ensure that work on Parkinson’s continues to develop. Research is, of course, crucial for discovering new drugs and underpins the entire drug discovery and development process. Produodopa is a groundbreaking new treatment for Parkinson’s disease, particularly for patients with advanced disease and severe motor fluctuations.”
“Research has been touched on by many speakers. It advances our understanding of Parkinson’s as we develop new treatments, technologies and management strategies. Today these things help people to live well with Parkinson’s; tomorrow they could deliver a cure. The Government are strongly committed to supporting research into Parkinson’s disease. We continue to encourage research through targeted funding, infrastructure support, policy initiatives, and collaboration and partnerships. For example, the UK Dementia Research Institute, which is primarily funded by Government, is partnering with Parkinson’s UK to establish a new £10 million research centre dedicated to better understanding the causes of Parkinson’s and finding new treatments.”
“Last November, we established the Neuro Forum—a UK-wide, Government-led forum focusing on services and support for people affected by neurological conditions. It is the first of its kind and brings together the Department of Health and Social Care, NHS England, devolved Governments and health services, and neurological alliances across the UK to address gaps in treatment and care and to drive improvements in neurological health across the four nations. The forum will focus on practical things, such as a better understanding of neurological workforce challenges and help to address them; teaching other staff to provide better care for people living with one or more of over 600 neurological conditions including Parkinson’s; sharing innovative solutions, such as new therapies; and, crucially, ensuring that patients’ voices are heard.”
“NHS England’s neuroscience transformation programme improves Parkinson’s care by focusing on faster diagnosis, better co-ordinated care and improved access to specialist services. For example, it contributes to shifting our NHS from hospital to community and from analogue to digital through the home-based care pathway. That focuses on providing comprehensive support and care for individuals in their own homes, integrating remote monitoring through wrist-worn sensors, and providing symptom management advice and access to healthcare professionals. Empowering patients to manage their condition at home means we can improve their quality of life and, crucially, maintain their dignity and independence.”
“People with Parkinson’s who are over 60 years old are entitled to free prescriptions, and for those who do need to pay, the cost can be capped by purchasing a prepayment certificate. In addition, the NHS low-income scheme can provide help with health costs on an income-related basis. My hon. Friend the Member for Dunfermline and Dollar asked me to meet several stakeholder organisations, and I am more than happy to meet them to discuss the Parky charter. I understand that Parkinson’s Connect is being piloted with six healthcare teams in England and Scotland, with more planned in 2025. I would be pleased to discuss how the pilots are providing comprehensive support to people with Parkinson’s on how they are progressing and on next steps.”
“The blue badge eligibility criteria in England were extended in 2019 to include more people with non-visible disabilities, in order to ensure that people with the greatest needs, whatever their disability or condition, have access to a badge. There are several automatic qualifying criteria for a blue badge, such as being in receipt of certain benefits. People who do not automatically qualify due to receiving certain benefits may still be eligible, and local authorities will assess applications based on the information provided. There are currently no plans to add to the list of conditions that give entitlement for free prescriptions. However, approximately 89% of prescription items are currently dispensed free of charge, and a wide range of exemptions are already in place.”
“The Government recently brought forward a Green Paper on the health and disability benefits system and the support we offer entitled “Pathways to Work”. In that, we consider how to improve the system for those with very severe health conditions and disabilities, which includes exploring ways to reduce the need for some people with severe health conditions to undergo a full PIP functional assessment. I am due to meet the DWP Minister next week. I will raise the issues that have been raised today with her, particularly by my hon. Friend the Member for Dunfermline and Dollar, the hon. Member for Strangford and others. The primary focus of the Department for Transport’s blue badge scheme is to help those with the greatest mobility needs and it is not condition-specific.”
“NHSE published a new elective reform plan in January, setting out the steps towards meeting this target by the end of this Parliament, and we achieved our pledge to deliver an additional 2 million elective appointments between July and November 2024, compared with the same period in 2023, seven months ahead of schedule. That is a first step to delivering our commitment that 92% of patients will wait no longer than 18 weeks from referral to consultant-led treatment by March 2029. The Department for Work and Pensions offers personal independence payments to individuals with health conditions or disabilities. However, there is currently no automatic entitlement to PIP in relation to any specific health condition except in cases of people nearing end of life.”
“There are initiatives nationally that support service improvement and better care for Parkinson’s patients. NHS England’s Getting it Right First Time neurology programme supports improvements to Parkinson’s care by promoting data-driven approaches, sharing best practices and fair access to services. It focuses on improving patient experiences, shining a spotlight on disparities in care and calling for well-integrated processes, such as people getting their meds on time. The NHS constitution handbook sets out that patients should start consultant-led treatment within 18 weeks from referral.”
“We also now have the Parky charter, which is galvanising public and professional awareness of the needs of the Parkinson’s community to ensure timely diagnosis, comprehensive care and dignity for all people with Parkinson’s. We recognise the challenges of living with Parkinson’s and hear the calls from the Parkinson’s community for more research, shorter waiting times for neurology appointments and more Parkinson’s nurses and multi- disciplinary teams to deliver Parkinson’s care. The Parkinson’s UK website has given a voice to many patients living across the country, and I want to echo the comments made by Andrew in the west midlands that our Parkinson’s nurses are “worth their weight in gold.” Neurology is particularly challenging, and we need more neurologists and specialist nurses.”
“In particular, I was moved to see how many people had contributed to the “Knit it Blue” campaign, sending in more than 500 beautiful knitted tulips. I also pay tribute to the Movers and Shakers, whose podcast is doing a fantastic job of raising awareness and advocating for better care and treatment for those living with Parkinson’s. Awareness campaigns really deliver results. We just need to look at the “Get It On Time” campaign, which has led to more than 100 NHS organisations pledging to improve the delivery of time-critical medication—raised a number of times in this debate—and is backed by resources and training materials commissioned by NHS England.”
“Friends the Member for Glasgow West (Patricia Ferguson), for Stirling and Strathallan (Chris Kane), for Hertford and Stortford (Josh Dean), for Ilford South (Jas Athwal) and for Bathgate and Linlithgow (Kirsteen Sullivan) and the Members for Aberdeenshire North and Moray East (Seamus Logan) and for Strangford (Jim Shannon) all raised various issues, it is fair to say that everybody who has spoken today, including those who made contributions from the Opposition Front Benches, have raised the importance of the voluntary and community sector and shared some powerful and important stories from their constituents. April was Parkinson’s Awareness Month and I pay tribute to the fantastic charities that make it a success: Parkinson’s UK, Cure Parkinson’s and The Brain Charity, to name but a few.”